Free Trial

InMed Pharmaceuticals (INM) Competitors

InMed Pharmaceuticals logo
$2.13 -0.02 (-0.93%)
As of 11:28 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

INM vs. LSTA, CLSD, PCSA, TRAW, APLM, SYBX, HOTH, FNCH, EGRX, and LIXT

Should you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Lisata Therapeutics (LSTA), Clearside Biomedical (CLSD), Heatwurx (PCSA), Traws Pharma (TRAW), Apollomics (APLM), Synlogic (SYBX), Hoth Therapeutics (HOTH), Finch Therapeutics Group (FNCH), Eagle Pharmaceuticals (EGRX), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry.

InMed Pharmaceuticals vs. Its Competitors

Lisata Therapeutics (NASDAQ:LSTA) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

In the previous week, Lisata Therapeutics had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 2 mentions for Lisata Therapeutics and 1 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of -0.50 beat Lisata Therapeutics' score of -0.77 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Lisata Therapeutics Negative
InMed Pharmaceuticals Negative

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 1.4% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

InMed Pharmaceuticals has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lisata Therapeutics$1.07M19.76-$19.99M-$2.23-1.08
InMed Pharmaceuticals$4.94M1.03-$8.16M-$12.09-0.18

Lisata Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

Lisata Therapeutics has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -165.12%. Lisata Therapeutics' return on equity of -69.68% beat InMed Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lisata TherapeuticsN/A -69.68% -59.44%
InMed Pharmaceuticals -165.12%-93.19%-74.49%

Lisata Therapeutics currently has a consensus price target of $23.50, suggesting a potential upside of 873.08%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Lisata Therapeutics is more favorable than InMed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
InMed Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Lisata Therapeutics beats InMed Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get InMed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INM vs. The Competition

MetricInMed PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.07M$2.65B$6.16B$10.63B
Dividend YieldN/A57.79%5.72%4.85%
P/E Ratio-0.1824.0529.4627.34
Price / Sales1.03588.41494.53190.41
Price / CashN/A27.2425.8230.35
Price / Book0.325.4412.476.68
Net Income-$8.16M$33.06M$3.32B$276.16M
7 Day Performance-3.18%2.54%2.19%0.09%
1 Month Performance-6.99%11.77%8.99%3.88%
1 Year Performance-63.28%-1.24%64.06%33.52%

InMed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INM
InMed Pharmaceuticals
0.4763 of 5 stars
$2.13
-0.9%
N/A-55.1%$5.07M$4.94M-0.1810Short Interest ↑
LSTA
Lisata Therapeutics
2.333 of 5 stars
$2.40
-1.2%
$23.50
+879.2%
-17.5%$21.02M$1M-1.0830Short Interest ↑
CLSD
Clearside Biomedical
1.494 of 5 stars
$4.00
+0.9%
$63.00
+1,477.0%
-76.3%$20.93M$1.66M-0.7230
PCSA
Heatwurx
2.473 of 5 stars
$0.41
-8.0%
$1.00
+146.3%
-77.3%$20.59MN/A-0.1820Negative News
Short Interest ↑
Gap Down
TRAW
Traws Pharma
0.7875 of 5 stars
$2.86
-1.3%
N/A-36.9%$20.57M$230K0.0317
APLM
Apollomics
0.2502 of 5 stars
$18.43
+51.3%
N/A+135.0%$20.27M$1.49M0.0045Gap Up
High Trading Volume
SYBX
Synlogic
N/A$1.73
+11.6%
N/A+22.7%$20.24M$10K-21.6380
HOTH
Hoth Therapeutics
2.6251 of 5 stars
$1.53
-0.3%
$4.50
+195.1%
+49.7%$20.22MN/A-1.434Positive News
Short Interest ↓
Gap Up
FNCH
Finch Therapeutics Group
1.8182 of 5 stars
$12.20
flat
N/A+2.5%$19.59MN/A-1.38190Short Interest ↓
EGRX
Eagle Pharmaceuticals
2.0909 of 5 stars
$1.50
-6.3%
N/A+43.3%$19.48M$257.55M0.00100Gap Down
LIXT
Lixte Biotechnology
0.1762 of 5 stars
$4.26
-1.8%
N/A+129.1%$19.18MN/A-3.264Gap Down

Related Companies and Tools


This page (NASDAQ:INM) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners